Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 12/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MAP2 | P11137 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | BCL9 | O00512 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16571044 | 0.90 | MPL (0.39) | XDHSLC22A12CYP2C8CYP2C9CYP11B2 | |
| SCHEMBL16571686 | 0.90 | XDH (0.39) | XDHSLC22A12CYP2C8CYP2C9MAP2 | |
| SCHEMBL16571862 | 0.88 | XDH (0.35) | XDHSLC22A12CYP2C8CYP2C9CYP11B2 | |
| SCHEMBL16571739 | 0.88 | XDH (0.40) | XDHSLC22A12CYP2C8CYP2C9PARP1 | |
| SCHEMBL16571180 | 0.86 | SLC22A12 (0.42) | XDHSLC22A12CYP2C9MAP2PARP1 | |
| SCHEMBL16571121 | 0.86 | XDH (0.39) | XDHSLC22A12CYP2C8CYP2C9BCL9 | |
| SCHEMBL16571716 | 0.85 | MAP2 (0.43) | XDHSLC22A12MAP2PARP1MET | |
| SCHEMBL16570776 | 0.85 | XDH (0.36) | XDHSLC22A12CYP2C8CYP2C9 | |
| SCHEMBL19478363 | 0.84 | SCN9A (0.41) | XDHSLC22A12MAP2PARP1 | |
| SCHEMBL16571057 | 0.84 | PARP1 (0.39) | XDHSLC22A12CYP2C8CYP2C9CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | claimed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | claimed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | claimed |
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3044207-B1 | INDOL-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464049-B2 | Indole-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| EP-3044207-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2015036412-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015036412-A1 | INDOL-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185721-A1 | INDOLE-CARBOXAMIDES | DRD2, HCRTR1, CDR2 | XDH 1297/4885SLC22A12 668/4885CYP2C8 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.